Drug intelligence / Profile preview

chloramphenicol + polymyxin b (Centaur Pharmaceuticals)

Development stage
Unknown
Lead developer
Centaur Pharmaceuticals
Modality
Small Molecules, Peptides
Administration
Ophthalmic, Otic
01

Overview

Ocupol is a fixed-dose combination ophthalmic and otic formulation containing the broad-spectrum bacteriostatic antibiotic chloramphenicol and the bactericidal lipopeptide antibiotic polymyxin B. Developed by Centaur Pharmaceuticals, Ocupol is approved for the treatment of superficial bacterial infections of the eye (such as bacterial conjunctivitis and blepharitis) and the external ear canal. Chloramphenicol exerts its antibacterial effect by reversibly binding to the bacterial 50S ribosomal subunit, thereby inhibiting protein synthesis. Polymyxin B targets Gram-negative bacteria by binding to lipopolysaccharides (LPS) in the outer membrane, disrupting membrane integrity and leading to cell lysis. Together, these active ingredients provide synergistic, broad-spectrum coverage against common ocular and otic bacterial pathogens.

Brand names
Ocupol
Other names
chloramphenicol + polymyxin b sulfatechloramphenicol and polymyxin bchloramphenicol/polymyxin b
02

Targets

Bacterial 50S ribosomal subunitBacterial inner membrane phospholipidMitoribosome (Mitochondrial ribosome)

Beyond the preview

Go deeper on chloramphenicol + polymyxin b (Centaur Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chloramphenicol + polymyxin b (Centaur Pharmaceuticals).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call